Yale Cancer Center Experts Present New Research at Hematology Annual Meeting
Physicians and scientists from Yale Cancer Center, part of Yale School of Medicine, will present new research at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, Calif., from December 9 to 12.
Discovering the 'Cytokine Language' That Activates Immune Responses
Using a new computational method based on a causal inference framework, CINEMA-OT, the Yale team studied how individual immune cells react to combinations of cytokines, or small proteins released by cells that regulate inflammation. They discovered that certain cytokines have a synergistic effect, inducing unique gene activation programs compared to their individual effects. This cryptography of cytokine signals acts as a language, instructing immune cells.
New Funding to Support Kidney Cancer Research in Braun Lab
The laboratory of David A. Braun, MD, PhD, has received approximately $5.75M in federal awards to fund mechanisms of response and resistance to immune therapy in kidney cancer at Yale Cancer Center. Funding from the National Cancer Institute and the Department of Defense will support new projects in Dr. Braun’s lab to investigate the immune microenvironment of renal cell carcinoma (RCC) or kidney cancer.
Determinants of Resistance to Nivolumab in Advanced Kidney Cancer
At the American Society of Clinical Oncology (ASCO) annual meeting, a study was presented that sought to evaluate why advanced renal cell carcinoma (RCC) patients receiving initial treatment with single-agent nivolumab (Opdivo) develop resistance to the PD-1 inhibitor. In this exclusive MedPage Today video, investigator David A. Braun, MD, PhD, of the Center of Molecular and Cellular Oncology at Yale Cancer Center in New Haven, Connecticut, discusses findings from the genomic and transcriptomic analysis and explains the next steps for the research.Source: MedPage Today
Combination Therapies Come of Age in Kidney Cancer
The American Society of Clinical Oncology meeting included a kidney cancer session that featured a presentation on combination therapies coming of age in kidney cancer by David A. Braun, MD, PhD opens in a new tab or window, of the Center of Molecular and Cellular Oncology at Yale Cancer Center in New Haven, Connecticut.Source: MedPage Today